Mixed quarterly results as Union Pacific and Western Union meet or beat expectations, while Euronet and Eastern Bank miss, and Amalgamated Financial delivers solid organic growth.
Novo Nordisk launches a $56.50 per share bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and highlighting the strategic value of Metsera's GLP-1 pipeline.
Mixed quarterly results as Union Pacific and Western Union meet or beat expectations, while Euronet and Eastern Bank miss, and Amalgamated Financial delivers solid organic growth.
Novo Nordisk launches a $56.50 per share bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and highlighting the strategic value of Metsera's GLP-1 pipeline.